>
Genu Recurvatum Market Size was valued at USD 0.32 Billion in 2023. The Global Genu Recurvatum industry is projected to grow from USD 0.53 Billion in 2024 to USD 1.48 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.98% during the forecast period (2024 - 2032).
Genu Recurvatum is a rare orthopedic complication in which the hyperextension of the knee is greater than five degrees. It is also known as back knee or knee hyperextension. It occurs more frequently in females than it does in males, and is commonly, identified in 0.5%-1.0% of patients undergoing Total knee arthroplasty (TKA). This condition causes stress in the posterior knee structures which cause permanent damage of the joint. Genu recurvatum can also cause other conditions such as knee pain or knee osteoarthritis. Genu recurvatum can be mild, moderate, or severe. This deformity can also arise from other medical conditions such as, quadriceps weakness, bone deformities, paralysis, plantar foot flexion, and high tibial ostotomies.
Genu recurvatum can be congenital or acquired. Congenital genu recurvatum (CGR) is an extremely rare condition, and found to be associated with other malformations such as talipes equinovarus, hip dysplasia, and absent patella. Signs and symptoms of this medical condition includes pain in the inner-leg portion of knee also known as medial tibiofemoral joint, pain in the outer back portion of knee also known as posterolateral ligamentous structures, extension of gait pattern, and difficulty in performing endurance activities.
Genu recurvatum can be of three types, i.e. external rotatory deformity (ERD), internal rotatory deformity (IRD), and non-rotatory deformity (NRD). Out of three, ERD, and NRD are more severe, as ERD leads to soft tissue damage in which lower legs angle outward. Whereas, NRD, produces stress to the posterior soft tissue structures of knee. In some developing, and under developed regions, burden of orthopedics condition is rising due to lack of awareness.
According to a study published in Indian Journal of Orthopaedics (IJO) in 2016, deficient orthopedic services and education such as, poor surgeon–patient ratio, poorly trained physicians to deal with musculoskeletal emergencies, and absence of minimum standard of orthopedic care, have been observed in some part of India. However, the Indian Orthopaedic Association (IOA) along with government health planners, individual medical practitioners, and medical educationists are working to find remedial solutions to these problems.
Notably, the market is expected to expand in the near future due to rise in geriatric population, high unmet needs of current treatment, and increase in research and development expenditure. Increase in aging population is the major market driver because the risk of orthopedic disorders increases exponentially with age. According to the data suggested by WHO in 2015, it is found that, worldwide, one in eight people was aged 60 years or over and by 2030, older people are projected to account for one in six people globally.
Despite these drivers, there are some issues associated with genu recurvatum market. High cost of treatment & management of genu recurvatum and related disorders, and lack of infrastructure in middle and low income countries may hamper the growth of the Genu Recurvatum Market.
Intended Audience
The Genu recurvatum market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, market is segmented into external rotatory deformity (ERD), internal rotatory deformity (IRD), and non-rotatory deformity (NRD).
On the basis of diagnosis, market is segmented into magnetic resonance imaging (MRI), X-rays, and others.
On the basis of treatment, market is classified into physical therapy, orthoses, bracing, and surgery.
On the basis of end-user, market is segmented into hospital, clinics, and others.
The Americas dominate the Genu recurvatum market owing to the rising awareness among people, and increasing healthcare expenditure. The Centers for Disease Control and Prevention (CDC) has stated that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States. Furthermore, increasing participation of bigger players and new marketers towards advancement in treatment approaches have also attracted a great deal of attention.
Europe holds the second position in the Genu recurvatum market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
Asia Pacific is the fastest growing Genu recurvatum market owing to the huge patient pool and developing healthcare technology.
The Middle East & Africa has the lowest market for rabies treatment market due to lack of technical knowledge and poor medical facilities.
Some of key the players in the Genu Recurvatum Market are:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)